Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Neurturin Polyclonal Antibody

Goat Polyclonal Antibody
Supplier: Invitrogen™ PA518768
Description
This antibody is tested in Peptide ELISA: antibody detection limit dilution 64,000.
Glial cell line-derived neurotrophic factor (GDNF) plays key roles in the control of vertebrate neuron survival and differentiation. A novel neurotrophic factor was recently cloned from human and mouse and designated neurturin. Physiological responses to neurturin (NTN) require the presence of receptor tyrosine kinase RET and a novel glycosylphosphatidylinositol linked receptor NTNRalpha. The cDNAs encoding NTNRalpha from human, rat, chicken, and mouse have been cloned recently and termed GDNFR-b, Ret ligand 2 (RETL2) or TGF-beta-related neurotrophic factor receptor 2 (TrnR2) and nominated as GFR-a-2 recently. NTN binds to and forms a complex with GFR-a-2 and the Ret PTK and activates the RET receptor tyrosine kinase pathway. Both NTN and GDNF can activate the MAP kinase and phosphatidylinositol 3-kinase pathways and play a critical role in the development of many neuronal populations. Neurturin and GDNF define a new family of neurotrophic factors.
Specifications
| Neurturin | |
| Polyclonal | |
| Unconjugated | |
| NRTN | |
| neurturin; NRTN; NTN; prepro-neurturin | |
| Goat | |
| Ammonium sulfate precipitation | |
| RUO | |
| 4902 | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Liquid |
| Immunohistochemistry (Paraffin), Western Blot | |
| 0.5 mg/mL | |
| TBS with 0.5% BSA and 0.02% sodium azide; pH 7.3 | |
| Q99748 | |
| NRTN | |
| Synthetic peptide sequence (DAHSRYHTVHELSARE) corresponding to the C-terminus amino acids of NRTN (aa 178-194). | |
| 100 μg | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction